Walking with modafinil and its use in Diplegic cerebral palsy: Retrospective review

Journal of Child Neurology

Volumn 21, Issue 4, 2006, Pages 294-297

  Hurst, Daniel L ^a   Lajara Nanson, Walter A ^a   Lance Fish, Margie E ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CENTRAL STIMULANT AGENT; MODAFINIL;

ARTICLE; CEREBRAL PALSY; CHILD; DISEASE SEVERITY; GAIT; HUMAN; MAJOR CLINICAL STUDY; MUSCLE TONE; PEDIATRICS; PREMATURITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SPASTICITY; STANDING; UNITED STATES; WALKING DIFFICULTY; WHEELCHAIR;

ADOLESCENT; BENZHYDRYL COMPOUNDS; CEREBRAL PALSY; CHILD; CHILD, PRESCHOOL; FEMALE; GAIT DISORDERS, NEUROLOGIC; HUMANS; INFANT; INFANT, NEWBORN; NEUROPROTECTIVE AGENTS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; WALKING;

EID: 33745153434     PISSN: 08830738     EISSN: None     Source Type: Journal    
DOI: 10.1177/08830738060210042001     Document Type: Article

References (32)

1. Hurst DL, Lajara-Nanson W: Use of modafinil in spastic cerebral palsy. J Child Neurol 2002;17:169-172.
2. Hurst DL, Lajara-Nanson WA, Dinakar P, et al: Retrospective review of modafinil use for cerebral palsy. J Child Neurol 2004;19:948-951.
3. Tilton AH: Management of spasticity in children with cerebral palsy. Semin Pediatr Neurol 2004;11:58-65.
4. Nelson KB: Epidemiology of Cerebral Palsy in the Year 2000. Presented at the 29th Annual Meeting of the Child Neurology Society, St. Louis, MO, October 28, 2000.
5. Blair EM, Love SC, Valentine JP: Proportional change: An additional method of reporting technical and functional outcomes following clinical interventions. Eur J Neurol 2001;8(Suppl 5):178-182.
6. Fenichel GM: Cerebral paraplegia and quadriplegia, in Fenichel GM (ed): Clinical Pediatric Neurology: A Sign and Symptoms Approach, 4th ed. Philadelphia, WB Saunders, 2001, 270-272.
7. Majnemer A, Mazer B: New directions in the outcome evaluation of children with cerebral palsy. Semin Pediatr Neurol 2004; 11: 11-17.
8. Wallace JD: Summary of combined clinical analysis of controlled clinical trials with tizanidine. Neurology 1994;44(Suppl 9):60-69.
9. Meythaler JM, Guin-Renfoe S, Johnson A, et al: Prospective assessment of tizanidine for spasticity due to acquired brain injury. Arch Phys Med Rehabil 2001;82:1155-1163.
10. Ketel WB, Kolb ME: Long-term treatment with dantrolene sodium of stroke patients with spasticity limiting the return of function. Curr Med Res Opin 1984;9:162-169.
11. Corbett M, Frankel HL, Michaelis L: A double blind, cross-over trial of Valium in the treatment of spasticity. Paraplegia 1972; 10:19-22.
12. Milla PJ, Jackson ADM: A controlled trial of baclofen in children with cerebral palsy. J Int Med Res 1977;5:398-404.
13. Medaer R, Hellebuyk H, Van Den Brande E, et al: Treatment of spasticity due to stroke. A double-blind, cross-over trial comparing baclofen with placebo. Acta Ther 1991;17:323-331.
14. Wong V. Use of botulinum toxin injection in 17 children with spastic cerebral palsy. Pediatr Neurol 1998;18:124-131.
15. Bottos M, Benedetti MG, Salucci V et al: Botulinum toxin with and without casting in ambulant children with spastic diplegia: A clinical and functional assessment. Dev Med Child Neurol 2003;45: 758-762.
16. Koman LA, Mooney JF, Smith BP, et al: Management of spasticity in cerebral palsy with botulinum-A toxin: Report of a preliminary, randomized, double-blind trial. J Pediatr Orthop 1994;14:299-303.
17. Gilmartin R, Bruce D, Strorrs B, et al: Intrathecal baclofen for management of spastic cerebral palsy: Multicenter trial. J Child Neurol 2000;15:71-77.
18. Schuele SU, Kellinghaus C, Shook SJ, et al: Incidence of seizures in patients with multiple sclerosis treated with intrathecal baclofen. Neurology 2005;64:1086-1087.
19. Parks TS, Owen JH: Surgical management of spastic diplegia in cerebral palsy. N Engl J Med 1992;326:745-749.
20. Hurst DL, Cedrone NJ: Modafinil for drooling in cerebral palsy. J Child Neurol 2006;21:112-114.
21. Montane E, Vallano A, Laporte JR: Oral antispastic drugs in non-progressive neurologic diseases: A systematic review. Neurology 2004;63:1357-1363.
22. Young RR, Delwaide P: Spasticity. N Engl J Med 1981;304:96-99.
23. Kita M, Goodkin DE: Drugs used to treat spasticity. Drugs 2000;59:487-495.
24. Tellez N, Montalban X: Modafinil and fatigue in multiple sclerosis. Neurologia 2004;19:434-437.
25. Zifko UA: Management of fatigue in patients with multiple sclerosis. Drugs 2004;64:1295-1304.
26. Becker P, Schwartz J, Feldman N, et al: Effect of modafinil on fatigue, mood, and health-related quality of life in patients with narcolepsy. Psychopharmacology 2004;171:133-139.
27. Jacobs I, Bell DG: Effects of acute modafinil ingestion on exercise time to exhaustion. Med Sci Sports Exerc 2004;36:1078-1082.
28. Haerer AF: Functions and disorders of function of certain non-cortical areas of the cerebrum, in Haerer AF (ed): DeJong's The Neurologic Examination, 5th ed. Philadelphia, JB Lippincott, 1992, 628-635.
29. Della Marca G, Restuccia D, Rubino M, et al: Influence of modafinil on somatosensory input processing in the human brain-stem. Clin Neurophysiol 2004;115:919-926.
30. Fishbain D, Cutler RB, Lewis J, et al: Modafinil for the treatment of pain-associated fatigue: Review and case report. J Pain Palliat Care Psychopharm 2004;18:39-47.
31. Manolio TA: Design and conduct of observational studies and clinical trials, in Gallin JI (ed): Principles and Practice of Clinical Research. San Diego, Elsevier, 2002, 190-193.
32. Sackett DL, Straus SE, Richardson WS, et al: Appendix 1: Confidence intervals, in Evidence-Based Medicine: How to Practice and Teach EBM, 2nd ed. Edinburgh, Churchill Livingstone, 2000, 233-244.